03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Organ transplant rejection Mouse studies suggest inhibiting CXCL13, CD40L and ICOSLG, which play roles in B cell maturation and activation, could help treat antibody-mediated lung transplant rejection. In a mouse model of antibody-mediated lung...
19:44 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint in a Phase IIb trial to treat moderate to severe active systemic lupus erythematosus (SLE) in patients receiving...
20:50 , Oct 23, 2018 |  BC Extra  |  Company News

Biogen halts vixotrigine development in painful lumbosacral radiculopathy

Biogen Inc. (NASDAQ:BIIB) will halt development of vixotrigine (BIIB074) for a pain indication after a Phase IIb miss disclosed in the biotech's 3Q18 earnings. Biogen beat total revenue and earnings estimates for the quarter, with...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Anti-CD40L Fab: Phase Ib started

UCB disclosed in its earnings for the 9 months ended Sept. 30 that it began a Phase Ib trial to evaluate CDP7657 in patients with SLE. Biogen Idec and UCB are co-developing CDP7657 to treat...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Biogen Idec, UCB, ALS TDI deal

Under a research agreement with Biogen Idec and UCB, the not-for-profit institute will conduct preclinical testing of the companies' CDP7657 to treat amyotrophic lateral sclerosis (ALS). After completing the study of the antibody targeting CD40...
07:00 , Aug 29, 2011 |  BioCentury  |  Strategy

R&D reboot

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc. 's new management has pruned the pipeline and instilled a new culture of intelligent risk...
08:00 , Jan 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis CD40 ligand (CD40LG; CD40L; CD154) Mouse studies suggest that inhibiting CD40L could help treat postmenopausal osteoporosis. In a mouse model of postmenopausal osteoporosis,...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc. , the outcome hardly looked like a slam dunk. Based on a pair...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Anti-CD40L Fab: Phase I started

UCB disclosed that it began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate single doses of CDP7657 in healthy volunteers and SLE patients. The company is co-developing the agent with Biogen Idec. Biogen Idec...